# Understanding personalised medical management for BPH patients at risk of progression

**Industry session by GLAXOSMITHKLINE**

**Sunday, 13 March**

**17:45 - 19:15**

**Location:** Room Stockholm (Hall B2, level 0)

**Chair:** P. Hammerer, Braunschweig (DE)

## Aims and objectives of this presentation

LUTS/BPH clinical guidelines nowadays support a personalised medical management based on patients risk of progression profile.

This symposium will highlight the importance of an evidence-based practice approach to optimally manage BPH patients considering patient concerns and best evidence.

This approach needs incorporates urologist and primary care physicians.

New evidence will be presented regarding patients preferences and concerns, differential diagnosis, the relevance of metabolic syndrome and further insights on patient profiles that would benefit most from medical treatment.

The symposium will be highly interactive including a lively and stimulating debate on implications in daily practice reflecting on the issues presented.

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 17:45 - 17:55 | **Welcome and introduction to a BPH patient journey**  
P. Hammerer, Braunschweig (DE) |
| 17:55 - 18:15 | **Implementing evidence-based practice to optimally manage BPH patients**  
A. Tubaro, Rome (IT) |
| 18:15 - 18:45 | **Evidence to support optimal treatment decisions in BPH patients at risk of progression**  
C.G. Roehrborn, Dallas (US) |
| 18:45 - 19:05 | **Moderator: Implications in daily practice**  
P. Hammerer, Braunschweig (DE) |
| 19:05 - 19:15 | **Wrap-up and closing remarks**  
P. Hammerer, Braunschweig (DE) |